FXN and Friedreich ataxia: A therapy able to increase the expression of frataxin protein is an attractive treatment approach for FA; residual frataxin protein levels in FA are reduced to 5–35% of healthy individuals, while carriers of the GAA expansion having approximately 50% of normal frataxin expression are asymptomatic28.